National Bank of Canada
MRNA icon

National Bank of Canada’s Moderna MRNA Stock Holding History

National Bank of Canada’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$99.8M Sell
1,424,802
-392,199
-22% -$20.3M 0.07% 208
2026
Q1 		$92.3M Sell
1,817,001
-339,274
-16% -$15.8M 0.08% 195
2025
Q4 		$63.6M Sell
2,156,275
-548,563
-20% -$14.9M 0.06% 271
2025
Q3 		$69.9M Buy
2,704,838
+2,112,644
+357% +$58.9M 0.07% 229
2025
Q2 		$16.3M Sell
592,194
-432,917
-42% -$11.4M 0.02% 617
2025
Q1 		$29.1M Buy
1,025,111
+856,036
+506% +$30.4M 0.03% 422
2024
Q4 		$7.03M Sell
169,075
-66,191
-28% -$3.16M 0.01% 883
2024
Q3 		$15.7M Buy
235,266
+90,739
+63% +$8.33M 0.02% 548
2024
Q2 		$16.8M Sell
144,527
-50,897
-26% -$6.44M 0.02% 433
2024
Q1 		$22.9M Sell
195,424
-114,956
-37% -$11.6M 0.04% 369
2023
Q4 		$34.9M Sell
310,380
-404,181
-57% -$34M 0.06% 295
2023
Q3 		$73.8M Buy
714,561
+564,679
+377% +$63M 0.11% 167
2023
Q2 		$18.2M Buy
149,882
+99,989
+200% +$13.3M 0.03% 384
2023
Q1 		$7.7M Buy
49,893
+20,234
+68% +$3.34M 0.02% 486
2022
Q4 		$5.33M Sell
29,659
-55,235
-65% -$9.03M 0.01% 593
2022
Q3 		$10M Buy
84,894
+70,864
+505% +$10.8M 0.05% 364
2022
Q2 		$2.03M Sell
14,030
-104,967
-88% -$15M 0.01% 795
2022
Q1 		$20.3M Buy
118,997
+108,203
+1,002% +$18.2M 0.06% 288
2021
Q4 		$2.69M Buy
+10,794
New +$3.16M 0.01% 732

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

National Bank of Canada's MRNA Position: Q2 2026 in Review

National Bank of Canada reduced its Moderna (MRNA) stake by 22% in Q2 2026, selling an estimated $20.3M and leaving 1,424,802 shares worth $99.8M. The position accounts for 0.07% of the portfolio, ranked #208.

National Bank of Canada first reported a position in MRNA in Q4 2021 and has held it in 19 quarters since. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • National Bank of Canada held 1,424,802 shares of Moderna worth $99.8M as of Q2 2026.
  • National Bank of Canada sold 392,199 Moderna shares in Q2 2026, an estimated $20.3M.
  • Moderna made up 0.07% of National Bank of Canada's portfolio in Q2 2026, its #208 holding.
  • National Bank of Canada first reported a position in Moderna in Q4 2021 and has held it in 19 quarters since.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on National Bank of Canada's 13F filing for Q2 2026, filed 10 Aug 2026.